Wedbush Increases Vigil Neuroscience (NASDAQ:VIGL) Price Target to $23.00

Vigil Neuroscience (NASDAQ:VIGL) had its price target boosted by Wedbush from $22.00 to $23.00 in a research note released on Friday, Benzinga reports. Wedbush currently has an outperform rating on the stock.

A number of other research analysts have also issued reports on VIGL. JMP Securities reiterated a market outperform rating and set a $23.00 target price on shares of Vigil Neuroscience in a research report on Thursday, April 18th. HC Wainwright restated a buy rating and set a $24.00 price objective on shares of Vigil Neuroscience in a research report on Friday.

Vigil Neuroscience Stock Performance

Shares of Vigil Neuroscience stock opened at $4.37 on Friday. The firm has a 50-day simple moving average of $3.54 and a two-hundred day simple moving average of $3.32. Vigil Neuroscience has a fifty-two week low of $2.47 and a fifty-two week high of $10.22. The company has a market cap of $164.22 million, a P/E ratio of -2.06 and a beta of 2.00.

Vigil Neuroscience (NASDAQ:VIGL) last released its quarterly earnings results on Tuesday, May 7th. The company reported ($0.50) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.10. Equities research analysts forecast that Vigil Neuroscience will post -2.09 EPS for the current year.

Hedge Funds Weigh In On Vigil Neuroscience

Hedge funds and other institutional investors have recently made changes to their positions in the company. Strs Ohio acquired a new position in Vigil Neuroscience during the fourth quarter worth about $27,000. PEAK6 Investments LLC raised its holdings in Vigil Neuroscience by 66.0% in the 3rd quarter. PEAK6 Investments LLC now owns 23,796 shares of the company’s stock valued at $128,000 after acquiring an additional 9,459 shares during the last quarter. Finally, Vanguard Group Inc. lifted its stake in Vigil Neuroscience by 11.9% in the 1st quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after purchasing an additional 95,276 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.